Australia's Noxopharm up on promising results for pancreatic cancer drug candidate

Noxopharm

28/09/2023 04:54

** Shares of Noxopharm  NOX.AX  rise as much as 10.5% to
A$0.042, their highest level since Aug 1 
    ** Test results of the biotechnology co's novel dual-cell
CRO-67 preclinical drug candidate shows significantly reduced
tumour volume and slower growth
    ** CRO-67 is being developed by co as a potential treatment
for pancreatic cancer 
    ** Co sees biggest intraday jump since Aug 1
    ** Noxopharm down 73.8% YTD as of last close 
   

 (Reporting by John Biju in Bengaluru)
 ((John.Biju@thomsonreuters.com;))